IU Health to merge 2 downtown hospitals
Indiana University Health wants to merge two of its big downtown hospitals—University and Methodist—into one location, meaning either one or both would close or be converted to another use.
Health Care Businesses
Articles
Town waives fees to accelerate $17.6M senior-living project
Fishers will forgive as much as $300,000 in development fees to get a $17.6 million expansion project started by Aug. 1.
Former Riley Hospital CEO Pescovitz to join Eli Lilly
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
Lilly consolidated into testosterone drug lawsuit
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
Republicans offer alternative VA health care bill
A bill proposed by four Senate Republicans would give veterans more flexibility to see a private doctor if they are forced to wait too long for an appointment at a Veterans Affairs hospital or clinic.
Costly drugs force cancer docs to weigh price with therapy
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
OurHealth to add employer clinics, 450 jobs by 2018
The 5-year-old firm has pledged to invest $20 million to double the size of its corporate headquarters in Indianapolis and lease real estate for a series of 3,500-square-foot health clinics across the state.
Lilly, Sanofi seek to sell erection drug Cialis without prescription
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
Ex-Lilly partner wins latest suit over Actos’ cancer risk
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda denies hiding Actos cancer risks in Nevada trial
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Drugmaker hid diabetes drug’s cancer risks, lawyer says
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
UPDATE: AstraZeneca board rejects new offer from Pfizer
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Lilly to appeal $450M ruling over poisoned workers in Brazil
Brazilian federal prosecutors had accused a Lilly subsidiary of incinerating toxic waste at the plant that it operated until 2003.
Lilly says its once-daily insulin tops competitor’s drug
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
U.S. House votes to revive expired research tax credit
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
Bayer’s $14.2 billion Merck buy shows pharma strategy split
Bayer AG’s $14.2 billion acquisition of Merck & Co. is the latest in a series of big pharma deals and it exposes a deepening split in the way drugmakers approach their portfolios.
Endocyte shares plunge 60 percent after drug trial is stopped
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
Drug prices surge as generics, niche treatments eat profit
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.
Roche battles payment cuts while growing diagnostics business
New tests have helped Roche Diagnostics grow its North American revenue, excluding its troubled diabetes care business, 23 percent over the past five years. But the money for diagnostic tests continues to go down in key areas, noted CFO Wayne Burris.
Lilly trade-secret defendants released to home detention
The court noted that after the government filed a second indictment March 12, the trade-secret theft claims against Guoqing Cao and Shuyu Li were changed to wire fraud, and aiding and abetting and conspiracy to commit wire fraud.